Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Palbociclib Combine With Endocrine Therapy and Anti-HER2 Therapy in HR Positive and HER2 Positive Advanced Breast Cancer

NCT05969184 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.

NCT NCT05969184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05969184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Palbociclib Combine With Endocrine Therapy and Anti-HER2 Therapy in HR Positive and HER2 Positive Advanced Breast Cancer
Lead sponsor
Peking University Cancer Hospital & Institute
Phase
Phase 2
Overall status
Completed
Start date
December 12, 2021
Completion date
June 25, 2026
Enrollment
94 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasm female